Key facts
- Notable investors include Cites Startups.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Circa Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Circa Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Circa Therapeutics
Developer of novel therapies designed to target disease-causing proteins through molecular induced proximity modalities. The company designs protein degraders that utilise the body's natural disposal system to selectively eliminate harmful proteins involved in various diseases, enabling biopharmaceutical companies and research organizations to seek innovative drug development methods and new treatment modalities with therapeutic interventions.
- Sector
- Healthcare
- HQ
- Buenos Aires, Argentina
- Founded
- 2025
- Employees
- 3
- Website
- circatherapeutics.com/
- Ownership
- Privately Held (backing)
Circa Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Circa Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Circa Therapeutics in its N-PORT filings yet. We sweep new filings monthly.